Business
Dr. Tin-Chuen Yeung, Distinguished Former Director of Strategy and Business Development at Baxter Healthcare Accepts Position as Advisory Panel Member of Falcon Technologies
Dr. Tin-Chuen Yeung, Distinguished Former Director of Strategy and Business Development at Baxter Healthcare Accepts Position as Advisory Panel Member of Falcon Technologies.
About this update from Eco-growth Strategies Inc.
[{"type":"text","content":"SACRAMENTO, CA / ACCESSWIRE / June 11, 2019 / Falcon Technologies, Inc. (OTCPINK: FLCN), a company focused on the marketing, sale, and distribution of CBD products and products derived from industrial hemp is honored Dr. Tin-Chuen Yeung has formally accepted a position on its Scientific Advisory Board.Dr. Yeung is a pharmacologist and an experienced researcher in the healthcare industry. Besides his experience in research, he has substantial experience in intellectual property law, business development, technology evaluation and commercialization. He serves as an advisor to venture capital and start-up biotechnology companies throughout the United States. He has also served as a trusted advisor to Fortune 500 companies.Dr. Yeung is currently the President of Everest International, Inc., where he provides consulting services in management of intellectual property, patent filing and prosecution, intellectual property, due diligence for M&A's, technology licensing, technology commercialization, and business development.Dr. Yeung is formerly the Head of Strategic Development, Life Sciences, for the Chicago law firm Bell Boyd & Lloyd, LLC. He is admitted to practice patent law before the United States Patent Bar. At Bell Boyd & Lloyd, he was also with the Intellectual Property group responsible for patent prosecution in the areas of biotechnology, nanotechnology, agricultural biotechnology, pharmaceuticals, drug delivery technologies, medical devices and other life sciences. He also provides counseling to clients in patent filing strategies and management of intellectual property.Dr. Yeung served as a Director of Strategy & Business Development for the Biosciences Division at Baxter International, Inc., where he managed the strategic development for worldwide development, marketing and manufacturing of recombinant protein products. He also served as Director of Corporate Development for Baxter, responsible for management of Baxter's acquisitions, technology development, licensing, and strategic alliances.Dr. Yeung also worked for the G. D. Searle and NutraSweet Divisions of the Monsanto Company (MON) for several years as a research scientist, and as manager of business ventures managing the evaluation and commercialization of new technologies. Prior to joining Monsanto, he was a research fellow at Harvard Medical Scho...